US-based Celerion and the Korean Drug Development Fund (KDDF) have signed a collaboration agreement aimed at strengthening early phase clinical research in South Korea.
A memorandum of understanding (MoU) has been signed by Celerion and KDDF to provide drug development expertise and support for the emerging drug discovery and development industry in South Korea.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The agreement will support a sharing of knowledge between KDDF and Celerion, providing the framework for collaborations of mutual benefit to both organisations.
The collaboration will focus on developing innovative and efficient ways to bring Korean drug discoveries to the global market. It enhances both organisations’ ability to effectively apply principles of translational medicine to the development of innovative new drugs.
KDDF funded companies will have access to Celerion’s extensive experience and expertise in early clinical research and bioanalysis, as well as the global footprint of external partner sites.
Celerion will support all programmes with KDDF from the recently announced business expansion within the Biomedical Research Institute at Seoul National University Hospital, South Korea.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataKDDF CEO Dongho Lee said that the collaboration between KDDF and Celerion is for building effective partnerships between government, industry and academia.
"Together with Celerion, KDDF will be able to provide professional consulting services to the Korean research communities to advance the research activities and promote important innovation," Lee said.
